Cor Vasa 2004, 45(7):346-348

Use of recombinant activated factor VII in cardiac surgery

Tomáš Vaněk^*, Jakub Hrabák, Martin Jareš, Zbyněk Straka, Petr Brůček, Jan Votava, Martin Zeman

Kardiochirurgická klinika, Fakultní nemocnice Královské Vinohrady a 3. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

The authors present their experience with the administration of supranormal-therapeutic doses (90 µg/kg) of recombinant activated factor VII in seven cardiac surgery patients. Recombinant activated factor VII was used postoperatively in the presence of intractable bleeding, 5 patients underwent postoperative revision before administration. Use of recombinant activated factor VII was followed by a significant reduction in blood losses (p < 0.05) associated with a shortening of INR and aPTT in laboratory tests. No patient was re-operated. The authors consider the administration of recombinant activated factor VII a most effective technique for the treatment of massive hemorrhage.

Keywords: Cardiac surgery; Bleeding; Recombinant activated factor VII

Published: July 1, 2004  Show citation